A randomized, placebo-controlled, phase 1 study to evaluate the effects of TAK-063 on ketamine-induced changes in fMRI BOLD signal in healthy subjects

RATIONALE: Phosphodiesterase 10A inhibitor TAK-063 has shown effects that suggest efficacy in schizophrenia treatment. OBJECTIVE: This randomized, double-blind, placebo-controlled, incomplete-crossover study investigated effects of single oral administration of TAK-063 on ketamine-induced changes in...

Descripción completa

Detalles Bibliográficos
Autores principales: Yurgelun-Todd, Deborah A., Renshaw, Perry F., Goldsmith, Paul, Uz, Tolga, Macek, Thomas A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7018803/
https://www.ncbi.nlm.nih.gov/pubmed/31773211
http://dx.doi.org/10.1007/s00213-019-05366-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7018803/
https://www.ncbi.nlm.nih.gov/pubmed/31773211
http://dx.doi.org/10.1007/s00213-019-05366-1

Ejemplares similares